Jazz Pharmaceuticals ( (JAZZ) ) has released its Q4 earnings. Here is a breakdown of the information Jazz Pharmaceuticals presented to its investors.
Jazz Pharmaceuticals, a global biopharmaceutical company headquartered in Dublin, Ireland, is dedicated to developing life-changing medicines for serious diseases, focusing on sleep disorders, epilepsy, and oncology. The company has a diverse portfolio of marketed medicines and a robust pipeline of innovative therapeutics.
Jazz Pharmaceuticals reported record total revenues of $4.1 billion for the year 2024, with significant growth in key product lines such as Xywav and Epidiolex, which saw year-over-year revenue increases of 16% and 15%, respectively. The company also achieved a milestone with its oncology revenues surpassing $1.1 billion, marking a 9% growth from the previous year.
Key financial highlights include a 6% increase in total revenues year-over-year and a substantial rise in GAAP net income to $560.1 million, up from $414.8 million in 2023. The company also launched Ziihera, a new oncology product, in December 2024, following its FDA approval. Jazz Pharmaceuticals remains focused on advancing its pipeline, with plans to submit a supplemental New Drug Application for Zepzelca in the first half of 2025.
Looking ahead, Jazz Pharmaceuticals has provided 2025 financial guidance, projecting total revenues between $4.15 billion and $4.40 billion, representing continued top- and bottom-line growth. The company remains confident in its ability to deliver long-term shareholder value through disciplined capital allocation and the advancement of its diversified commercial portfolio.